Nanotechnology guided newer intervention for treatment of osteoporosis: efficient bone regeneration by up-regulation of proliferation, differentiation and mineralization of osteoblasts

Abstract

Owing to its versatility and superiority, nanotechnology-mediated interventions have gained remarkable recognition. The present study was aimed for efficient co-delivery raloxifene (RLX) and curcumin (CUR) as hyaluronic acid (HA)-modified nanoparticles (NPs). The fabricated NPs were optimized for suitable physicochemical characteristics and evaluated for bone remodeling potential. Results showed that HA-RLX/CUR NPs exhibited excellent physicochemical characteristics and remained stable upon storage in refrigerator. Assessment of various aspects of cell growth cycle evidenced promising bone regeneration efficacy of HA-RLX/CUR NPs. This new strategy of employing simultaneous delivery of anti-resorptive and bone forming agents would be an efficient pharmacotherapy for treatment of osteoporosis.

Graphical Abstract

ABBREVIATIONS

RLX: Raloxifene; CUR: Curcumin; NPs: Nanoparticles; HA: Hyaluronic acid; HA-RLX/CUR NPs: Hyaluronic acid coated raloxifene/curcumin co-loaded nanoparticles; SERMs: Selective estrogen receptor modulators; FDA: Food and Drug Administration; PDI: size distribution index; %EE: Percent entrapment efficiency; %LC: Loading capacity; DMEM: Dulbecco’s Modified Eagle Medium; CS: Chitosan; PVA: Polyvinyl alcohol; ARS: Alizarin Red S; OCN: Osteocalcin; BMP-2: Bone morphogenetic protein-2; Runx-2: Runt-related transcription factor 2

Keywords:

• Co-administration
• curcumin
• hyaluronic acid
• nanotechnology
• osteoporosis
• raloxifene

Acknowledgements

Authors would like to greatly acknowledge College of Pharmacy, University of Sharjah for providing resources and support in accomplishing this research project.

Disclosure statement

The authors report no declaration of interest in the present work.